Abstract

BackgroundHepatitis C virus infection (HCV) has a significant global health burden with an estimated 2%–3% of the world's population infected, and more than 350,000 dying annually from HCV-related conditions including liver failure and liver cancer. Prisons potentially offer a relatively stable environment in which to commence treatment as they usually provide good access to health care providers, and are organised around routine and structure. Uptake of treatment of HCV, however, remains low in the community and in prisons. In this study, we explored factors affecting treatment uptake inside prisons and hypothesised that prisoners have unique issues influencing HCV treatment uptake as a consequence of their incarceration which are not experienced in other populations.Method and FindingsWe undertook a qualitative study exploring prisoners' accounts of why they refused, deferred, delayed or discontinued HCV treatment in prison. Between 2010 and 2013, 116 Australian inmates were interviewed from prisons in New South Wales, Queensland, and Western Australia. Prisoners experienced many factors similar to those which influence treatment uptake of those living with HCV infection in the community. Incarceration, however, provides different circumstances of how these factors are experienced which need to be better understood if the number of prisoners receiving treatment is to be increased. We developed a descriptive model of patient readiness and motivators for HCV treatment inside prisons and discussed how we can improve treatment uptake among prisoners.ConclusionThis study identified a broad and unique range of challenges to treatment of HCV in prison. Some of these are likely to be diminished by improving treatment options and improved models of health care delivery. Other barriers relate to inmate understanding of their illness and stigmatisation by other inmates and custodial staff and generally appear less amenable to change although there is potential for peer-based education to address lack of knowledge and stigma.

Highlights

  • Hepatitis C virus infection (HCV) has a significant global health burden with an estimated 2%–3% of the world’s population infected, and more than 350,000 dying annually from HCVrelated conditions including liver failure and liver cancer [1].Prisons potentially offer a relatively stable environment in which to commence treatment, organised around routine and structure, and they usually provide good access to health care providers

  • We triangulated the data with perspectives from health service providers responsible for delivering HCV treatment to prisoners

  • HCV infection is very common among prisoners with an overall prevalence of 30%, and up to

Read more

Summary

Introduction

Hepatitis C virus infection (HCV) has a significant global health burden with an estimated 2%–3% of the world’s population infected, and more than 350,000 dying annually from HCVrelated conditions including liver failure and liver cancer [1].Prisons potentially offer a relatively stable environment in which to commence treatment, organised around routine and structure, and they usually provide good access to health care providers. Hepatitis C virus infection (HCV) has a significant global health burden with an estimated 2%–3% of the world’s population infected, and more than 350,000 dying annually from HCVrelated conditions including liver failure and liver cancer [1]. Almost half of all Australian prison inmates report injecting drug use with around 70% incarcerated for drug-related crimes [10]. Given this nexus, HCV infection is very common among prisoners with an overall prevalence of 30%, and up to. Hepatitis C virus infection (HCV) has a significant global health burden with an estimated 2%–3% of the world’s population infected, and more than 350,000 dying annually from HCV-related conditions including liver failure and liver cancer. We explored factors affecting treatment uptake inside prisons and hypothesised that prisoners have unique issues influencing HCV treatment uptake as a consequence of their incarceration which are not experienced in other populations

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.